Sign In
Buy NKTR
$59.23
+0.670 (+1.14%)
At Close: Jun 03, 2026
Why Is Nektar Therapeutics Stock Gaining Wednesday?
07:35am, Wednesday, 11'th Feb 2026
Nektar Therapeutics (NASDAQ: NKTR) stock surged in premarket trading Wednesday after new long-term data showed its experimental eczema therapy delivered sustained and even deepening disease control
Nektar Therapeutics (NKTR) Discusses 36-Week Maintenance Results From Phase 2b REZOLVE-AD Study in Atopic Dermatitis Transcript
04:24pm, Tuesday, 10'th Feb 2026
Nektar Therapeutics (NKTR) Discusses 36-Week Maintenance Results From Phase 2b REZOLVE-AD Study in Atopic Dermatitis Transcript
Nektar Therapeutics Announces Proposed Public Offering
04:05pm, Tuesday, 10'th Feb 2026
SAN FRANCISCO, Feb. 10, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherap
71% and 83% of patients maintained EASI-75 responses and 85% and 63% maintained vIGA-AD 0/1 responses with 24 µg/kg monthly and quarterly dosing, respectively Meaningful improvement in responses obs
Critical Review: Polydex Pharmaceuticals (OTCMKTS:POLXF) and Nektar Therapeutics (NASDAQ:NKTR)
01:30am, Tuesday, 10'th Feb 2026
Nektar Therapeutics (NASDAQ: NKTR - Get Free Report) and Polydex Pharmaceuticals (OTCMKTS:POLXF - Get Free Report) are both medical companies, but which is the better business? We will contrast the tw
SAN FRANCISCO, Feb. 9, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of novel immunology therapies, today announced it will
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:10pm, Friday, 30'th Jan 2026
SAN FRANCISCO, Jan. 30, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on January 21, 2026, the Organization and Compensation Committee of Nektar's Board of Directors g
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
10:00am, Thursday, 22'nd Jan 2026
NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR). Such investors are advised to
Emerald Advisers LLC Takes Position in Nektar Therapeutics $NKTR
04:53am, Thursday, 22'nd Jan 2026
Emerald Advisers LLC bought a new stake in Nektar Therapeutics (NASDAQ: NKTR) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institution
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
04:20pm, Tuesday, 20'th Jan 2026
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR). Such investors are a
Nektar.io Introduces DIRT: Materials Management for the Construction Industry
06:58pm, Thursday, 15'th Jan 2026
Edmonton, Alberta--(Newsfile Corp. - January 15, 2026) - Nektar.io, located at 14420 154 Ave NW, Edmonton, Alberta, T6V 0K8, Canada, a provider of operational software for the construction industry to
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
10:00am, Thursday, 15'th Jan 2026
NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR). Such investors are advised to
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
04:28pm, Tuesday, 13'th Jan 2026
NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR). Such investors
Nektar Therapeutics (NASDAQ:NKTR) Shares Pass Above 200 Day Moving Average – Here’s What Happened
03:08am, Friday, 09'th Jan 2026
Nektar Therapeutics (NASDAQ: NKTR - Get Free Report) shares passed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $43.51 and traded as high as $
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
10:00am, Thursday, 08'th Jan 2026
NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR). Such investors are advised to
